Characterization of a novel brain barrier ex vivo insect-based P-glycoprotein screening model by Andersson, O et al.
ORIGINAL ARTICLE
Characterization of a novel brain barrier ex vivo
insect-based P-glycoprotein screening model
Olga Andersson1, Liesbeth Badisco2, Ane Hakansson Hansen1, Steen Honore Hansen3,
Karin Hellman1, Peter Aadal Nielsen1, Line Rørbæk Olsen3, Rik Verdonck2, N. Joan Abbott4,
Jozef Vanden Broeck2 & Gunnar Andersson1,
1EntomoPharm, R&D, Medicon Village, S-223 81, Lund, Sweden
2Department of Animal Physiology and Neurobiology, Katholieke Universiteit Leuven, Leuven, Belgium
3Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100, Copenhagen, Denmark
4BBB Group, Institute of Pharmaceutical Science, King0s College London, Franklin Wilkins Building, London, SE1 9NH, United Kingdom
Keywords
Brain–barrier permeability, efflux transporter,
insect brain barrier, Pgp-transporter,
screening model
Correspondence
Gunnar Andersson, EntomoPharm R&D,
Medicon Village, S-223 81 Lund, Sweden.
Tel: +46 (0) 733-826-706; Fax: +46 (0) 462-
756-010; E-mail: gunnar.andersson@
biocabris.se
Funding Information
This study was supported by The Danish
National Advanced Technology Foundation
(grant 023-2011-3). Funding was provided to
L. B., R. V., and J. V. B. by the Interuniversity
Attraction Poles program (Belgian Science
Policy Grant [P7/40]) and the Flemish
Research Foundation (FWO) and KU Leuven
Research Foundation (grant [GOA/11/02]).
Received: 25 February 2014; Revised: 2 April
2014; Accepted: 3 April 2014
Pharma Res Per, 2 (4), 2014, e00050,
doi: 10.1002/prp2.50
doi: 10.1002/prp2.50
Abstract
In earlier studies insects were proposed as suitable models for vertebrate blood–
brain barrier (BBB) permeability prediction and useful in early drug discovery.
Here we provide transcriptome and functional data demonstrating the presence
of a P-glycoprotein (Pgp) efflux transporter in the brain barrier of the desert
locust (Schistocerca gregaria). In an in vivo study on the locust, we found an
increased uptake of the two well-known Pgp substrates, rhodamine 123 and
loperamide after co-administration with the Pgp inhibitors cyclosporine A or
verapamil. Furthermore, ex vivo studies on isolated locust brains demonstrated
differences in permeation of high and low permeability compounds. The verte-
brate Pgp inhibitor verapamil did not affect the uptake of passively diffusing
compounds but significantly increased the brain uptake of Pgp substrates in the
ex vivo model. In addition, studies at 2°C and 30°C showed differences in brain
uptake between Pgp-effluxed and passively diffusing compounds. The transcrip-
tome data show a high degree of sequence identity of the locust Pgp transporter
protein sequences to the human Pgp sequence (37%), as well as the presence of
conserved domains. As in vertebrates, the locust brain–barrier function is mor-
phologically confined to one specific cell layer and by using a whole-brain
ex vivo drug exposure technique our locust model may retain the major cues
that maintain and modulate the physiological function of the brain barrier. We
show that the locust model has the potential to act as a robust and convenient
model for assessing BBB permeability in early drug discovery.
Abbreviations
ABC, ATP-binding cassette; AUC, area under curve; B/P, brain:plasma ratio; BBB,
blood–brain barrier; BCRP, breast cancer-resistant proteins; Cbz, carbamazepine;
CNS, central nervous system; CsA, cyclosporin A; KO, knockout; LLOQ, lower
limit of quantification; MDCK, Madin-Darby canine kidney; MDR1-MDCK,
MDR1-transfected MDCK; MDR1, multidrug resistance protein-1; NCBI, National
Center of Biotechnology Information; Pgp, P-glycoprotein; Rho123, rhodamine
123; SD, standard deviation; WT, wild type.
Introduction
The mammalian blood–brain barrier (BBB) is composed
of capillary endothelial cells that control the entry of
nutrients and xenobiotics to the brain and thus preserve
homeostasis of the neural microenvironment, a prerequi-
site for reliable neural transmission and function (Abbott
et al. 2006, 2010). However, the protection of brain func-
tion by the BBB restricts the permeation of drugs and
results in a low brain target exposure concentration being
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a major challenge in the discovery of new drugs for cen-
tral nervous system (CNS)-related diseases.
An important gate keeper in the vertebrate brain is the
ATP-driven P-glycoprotein (Pgp) efflux transporter (mul-
tidrug resistance protein-1[MDR1], ATP-binding cassette
[ABC] B1), localized to the endothelium forming the
BBB. The efficiency of the Pgp transporter in restricting
the uptake of therapeutic drugs has been demonstrated
several times, for example by comparing brain uptake in
Pgp knockout (KO) mice with uptake in wild type (WT)
(Schinkel 1999; Doran et al. 2005). The promiscuity of
the Pgp transporter enables it to efflux structurally unre-
lated hydrophobic amphipathic compounds, including
therapeutic drugs. The Pgp-imposed restriction of drug
permeation of the BBB has been a critical issue in the
drug discovery process resulting in significant efforts to
establish experimental models providing information on
CNS barrier efflux of test compounds. Although compari-
son of brain:plasma ratio (B/P) in WT and Pgp KO mice
generates solid Pgp information, this in vivo model is too
time-consuming to be used as standard screening model
in early drug discovery. Therefore, a number of cell-based
in vitro models have been developed and proposed as
useful tools in the drug discovery screening process and
in the identification of Pgp substrates and inhibitors
(Polli et al. 2001; Weiss et al. 2003; Mensch et al. 2009).
Two commonly employed systems are the renal cell
lines LLC-PK1 (porcine kidney epithelial cells) and
Madin-Darby canine kidney (MDCK). Both cell systems
are easy to grow and MDCK, transfected with the human
multidrug resistance gene MDR1 (MDR1-MDCK, MDR1-
transfected MDCK), is often used as an industrial screen-
ing model for identification of Pgp substrates (Feng et al.
2008). However, these cells are of epithelial origin and
compared to barrier endothelial cells, epithelial cells dis-
play differences in morphology, tight junction organiza-
tion, and transporter expression (Garberg et al. 2005;
Cecchelli et al. 2007; Abbott et al. 2008; Liu et al. 2008).
Furthermore, screening data from the MDCK model
showed that more than 70% of the non-CNS drugs exhib-
ited permeability above the level recommended for selec-
tion of CNS candidates. In addition, the MDR1-MDCK
cells possessed Pgp transporter activity markedly greater
than in vivo (Mahar Doan et al. 2002; Feng et al. 2008),
making the prediction of the in vivo properties problematic.
In general, CNS drugs should be characterized by rea-
sonable BBB permeability and low Pgp efflux while
peripheral-acting drugs should either be poorly permeat-
ing or substrates for efflux transporters, for example Pgp
or breast cancer-resistant proteins (BCRP). Pgp is the
most intensively studied transporter and it is a major
concern to the pharmaceutical industry (Liu et al. 2008).
In a comprehensive study using Pgp (mdr1a/b) KO and
WT mice, it was confirmed that the majority of the 32
most prescribed CNS drugs showed no or weak Pgp-med-
iated transport (Doran et al. 2005). From another study
(Mahar Doan et al. 2002), using the in vitro MDR1-
MDCK model, it was found that the majority of the non-
CNS drugs exhibited a permeability rate that overlapped
that of the CNS drugs, demonstrating much lower accu-
racy in this model compared to the in vivo KO/WT Pgp
discrimination. These discrepancies most probably reflect
higher paracellular permeability due to less functional
tight junctions of the MDR1-MDCK cells but could also
be influenced by the overexpression or background
expression of Pgp transporter in transfected and WT
cells (Taub et al. 2005; Kuteykin-Teplyakov et al. 2010).
For this reason the need for models that have permeabil-
ity and transporter characteristics more similar to those
of the vertebrate BBB has been emphasized (Liu et al.
2008).
Recently we found, using a locust brain barrier model,
that the Pgp inhibitor verapamil significantly increased
uptake of the Pgp substrate quinidine into the locust
brain (Nielsen et al. 2011). This observation was strongly
supported by the documentation in the fruit fly (Drosophila
melanogaster, Dm) of the mammalian Pgp transporter
homologue (Mdr65) (Mayer et al. 2009). Here we have
characterized the locust model in vivo by intrahemolym-
phic injection of the test compound and ex vivo under
controlled test compound exposure conditions.
Materials and Methods
Animals
Desert locusts, Schistocerca gregaria (Sg), were obtained
from a commercial animal breeder (Petra Aqua, Prague,
Czech Republic). On arrival the locusts were housed
under crowded conditions in an insect room and adapted
to a 12:12 h dark/light cycle. The locusts were maintained
in colonies at a local terrarium temperature of 30–34°C.
The animals were fed Chinese cabbage and wheat bran ad
libitum. All experiments were carried out on fifth instar
locusts and 2–3 weeks after adult emergence.
Chemicals
The following compounds were obtained from Sigma-
Aldrich (Stockholm, Sweden): atenolol, carbamazepine
(Cbz), loperamide, propranolol, rhodamine 123 (Rho123),
quinidine, and verapamil. Cyclosporin A (CsA; Sandim-
mun, 50 mg/mL, Novartis, T€arby, Sweden) was purchased
from the drug store, Apoteket AB (Lund, Sweden). All
other chemicals were analytical reagent grade and were pur-
chased from Sigma-Aldrich.
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Test solution preparation
Stock solutions were prepared by dissolving the test com-
pounds in 100% dimethyl sulfoxide (DMSO). Final test
solution concentrations were obtained by diluting stock
solutions in 4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid (HEPES)-buffered insect buffer with the following
composition: NaCl 147 mmol/L, KCl 10 mmol/L, CaCl2
4 mmol/L, NaOH 3 mmol/L, and HEPES 10 mmol/L (pH
7.2). For in vivo studies, Rho123 and loperamide were
dissolved in H2O with 2.5% DMSO as final concentration
and CsA (Sandimmun) diluted with saline. Verapamil was
dissolved in insect buffer.
In vivo experiments
Drugs were administrated into the hemolymph by insert-
ing the needle (27G 9 ¾″) of a 100 lL Hamilton syringe
between two terga of the abdomen of the locust. 40 lL of
the test compound solution was injected into the hemol-
ymph. The test compounds were dosed using the follow-
ing concentrations: Rho123 at 1.25 mg/mL, loperamide at
2.5 mg/mL, and CsA at 1.2 mg/mL. After 15 min expo-
sure at room temperature (20°C) 10 lL hemolymph was
sampled using Disposable Capillary Pipettes “end to end”
and transferred to 40 lL ice-cooled insect buffer in
a 1.5 mL microcentrifuge tube (Eppendorf, Nordic,
Ho¨rsholm, Denmark). Hemolymph proteins were precipi-
tated and further prepared for analysis as described below.
The brain of the treated animal was immediately dis-
sected after hemolymph sampling by cutting off the frontal
part of the head, through the esophagus. Following removal
of the neural lamella (the outer connective tissue layer), the
brains were washed in ice-cold insect buffer and transferred
to 1.5 mL microcentrifuge tubes (Eppendorf) containing
50 lL ice-cold insect buffer. The brains where further pre-
pared for analysis as described below. (The size of the desert
locust brain in males and females was determined as
1.60  0.09 mg and 1.68  0.16 mg, respectively [n = 12].)
The brain uptake of the test compound is related to
the brain exposure but since the test compound concen-
tration in the hemolymph may vary between individual
animals, we base the comparisons on brain:hemolymph
ratios rather than on absolute brain concentrations.
Clearance of test compounds from the hemolymph was
measured by repeated sampling of 10 lL hemolymph
from the individual locust at 5, 15, 45, 120, and 360 min
after intrahemolymph administration (20 lL) of the test
compound solution (20 lmol/kg body weight). The
10 lL hemolymph samples were added to microcentrifuge
tubes (Eppendorf) containing 40 lL ice-cold insect buffer.
Hemolymph proteins were precipitated and further pre-
pared for analysis as described below.
Precipitation of proteins in the brain and hemolymph
samples was done by addition of 100 lL of a 2% zinc
sulfate in 50% methanol solution to a final volume of
150 lL. The brain tissue was homogenized with an ultra-
sonic probe (Bandelin Electronic, Berlin, Germany) for
8 sec at a power of 19%. After homogenization all sam-
ples were centrifuged at 10 000g for 5 min at 4°C and
100 lL of the supernatant transferred to Crimp l-Vials
(ScantecLab, G€oteborg, Sweden) for analysis.
Ex vivo experiments
The brain was dissected from the head as described
above. The three merged ganglia of the brain (protocere-
brum, deutocerebrum, and tritocerebrum) were prepared
using fine forceps and the connections to the compound
eyes were removed (Fig. 1). The brain was dissected free
from fat and exposed to the test compounds in a micro-
well plate (96U Microwell Plates; Sigma-Aldrich, Stock-
holm, Sweden) containing 250 lL of the test solution
heated to 30°C in a block thermostat (HLC Technologies,
Pforzheim, Germany). During model development the
accuracy of the dissection procedure, to avoid affecting
the tightness of the brain barrier, was repeatedly moni-
tored using atenolol as a control. After a standard expo-
sure time of 5 min the brains were removed from the
wells and washed twice in ice-cold insect buffer. Follow-
ing removal of the neural lamella (the outer connective
tissue layer), the brains were transferred to 1.5 mL micro-
centrifuge tubes (Eppendorf) containing 50 lL ice-cold
insect buffer. Protein precipitation and brain tissue
homogenization were performed as described above.
Histology
Locust brains were fixed in 4% phosphate-buffered para-
formaldehyde for 8 h and then washed in PBS and frozen
at 18°C. The fixed and frozen brains were cut in 10 lm
sections, the nuclei stained with bisbenzimide and the
slides photographed in an Olympus fluorescence micro-
scope. Some brains were incubated in insect buffers con-
taining red fluorescent 100 nm polystyrene nanoparticles
for 15 min before fixation to stain the neural lamella out-
side the barrier layer.
Quantitative analysis of drugs
in hemolymph and brain tissue
Supernatant from the brain homogenates was analyzed by
liquid chromatography-mass spectometry (LC-MS) using
an Agilent 1200 HPLC coupled to a MSD 1100 detector
(Agilent Technologies, Walbronn, Germany). The chro-
matographic column was a Phenomenex Kinetex (Værløse,
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Denmark), 50 9 4.6 mm with 2.6 lm particles and was
kept at 30°C. The mobile phase A was 0.1% formic acid
and mobile phase B was 0.1% formic acid in methanol
and analysis was performed using gradient elution from
5% to 90% mobile phase B. Detection was performed in
SIM mode using the appropriate [M+1]+ ions in positive
mode. Calibration standard solutions were prepared of
the respective analytes in a similar way as the brain
homogenates using insect buffer and the zinc sulfate
reagent containing the internal standard. Quantities of
3-lL aliquot of the samples and the calibration standards
were injected into the LC-MS system. The lower limit of
quantification (LLOQ) was typically in the range of
2 nmol/L in the final sample solution.
The measured concentrations in brain and hemolymph
are the total compound concentrations, that is free com-
pound plus compound bound to brain tissue and free
compound plus compound bound to hemolymph pro-
teins, respectively. This is in analogy to the corresponding
brain:plasma ratio measurements often performed in
mammalian studies (Hammarlund-Udenaes et al. 2008).
Identification of locust Pgp-like protein-
encoding transcripts
The human Pgp and the Dm Mdr65 protein sequences
were used as queries for a tblastn search (Altschul et al.
1997) in the Sg transcriptome sequence data (unpubl.
data from the research group of J. Vanden Broeck). Only
those hits showing an e-value of 0.0 (excellent tblastn
matches) for both queries were retained. The transcript
sequences that met this criterion were subsequently
retrieved from the database and verified by a reciprocal
blastx search in the nr protein database of the National
Center of Biotechnology Information (NCBI), restricted
to Homo sapiens and Dm sequence data. The transcript
sequences were translated by means of the ExPASy Trans-
lation Tool (http://www.expasy.org/tools/). The obtained
Sg protein sequences, together with the human Pgp and
Dm Mdr65 protein sequences were used as input for the
Clustal Omega alignment algorithm (Goujon et al. 2010;
Sievers et al. 2011).
Statistical analysis
All values are expressed as mean  standard deviation
(SD). To determine statistical significantly differences
among the experimental groups, the single-tailed
Student’s t-test was used. A P value of <0.05 was deemed
significant.
Results
In vivo brain uptake
Previously it has been shown that the Dm brain concen-
tration of Rho123 increases when the compound is co-
injected with the Pgp inhibitor CsA (Mayer et al. 2009).
To confirm this observation in Sg we have used the same
study protocol to document the uptake of Rho123 in the
locust brain. We also included the Pgp substrate lopera-
mide in the in vivo study since it is taken up in the
(A) (B)
Figure 1. Anatomy of locust brain. The locust brain comprises three pairs of ganglia that lie above the esophagus. (A) A dissected Schistocerca
gregaria brain, prepared for analysis, showing the bilobed brain consisting of the protocerebrum, deutocerebrum, and tritocerebrum. The
protocerebrum receives sensory information from the compound eyes and the ocelli while deutocerebrum is a center for olfactory signal input.
Tritocerebrum connects the insect brain via its circumesophageal connectives to the ventral nerve cord. (B) Section through the S. gregaria brain
showing the typical peripheral localization of nucleated cells in insects (glia and neuronal cells). Shaded areas show some main regions of
organized neuropil (for further information on the desert locust brain anatomy, see el Jundi et al. 2010).
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human brain when the Pgp efflux mechanism is inhibited
(Elkiweri et al. 2009). The test compounds were injected
alone or co-injected with CsA into the abdominal hemol-
ymph. 15 min after injection hemolymph samples were
collected and the brains were dissected for quantitative
determination of test compound concentration. While
there was no difference in hemolymph Rho123 or lopera-
mide concentrations when the compounds were injected
alone or co-injected with CsA (data not shown), there
was a significant increase in brain uptake of both com-
pounds when co-injected with CsA (Fig. 2).The utility of
the in vivo locust model for screening and selection of
potential CNS drugs could be challenged by the obvious
complication of a rapid clearance from the hemolymph of
the test drug and hence a drug-specific decrease in the
exposure concentration. By using repeated hemolymph
sampling (10 lL) from the individual locusts we indeed
found significant differences in clearance rates between
loperamide and quinidine, two Pgp substrates, and
between atenolol and propanolol, two compounds with
similar molecular structures (Table 1).
Ex vivo brain uptake
To provide the drug discovery process with a relevant
BBB permeability screening model, based on an in vivo
like “whole-brain principle” and not affected by the
hemolymph clearance of the test compound, we established
an ex vivo locust brain barrier model. In this model,
isolated locust brains are dissected from the insect and
placed in a test tube (or well) containing the test com-
pound dissolved in an insect buffer. In this setup, the
exposure concentration and temperature is constant dur-
ing the entire experiment. To validate the ex vivo model
using drugs with well-known permeability characteristics
we initially studied the concentration-dependent uptake
of Cbz and atenolol, two compounds with markedly dif-
ferent BBB permeability. As is shown in Figure 3, brain
uptake of the compounds in the ex vivo model was
markedly different but both compounds displayed a lin-
ear increase in the brain uptake, strictly correlated to the
exposure concentration, indicating that both compounds,
as expected, are permeating the brain barrier by passive
diffusion. When the ex vivo locust brains were exposed
to increasing concentrations of the well-known Pgp sub-
strates, quinidine and loperamide, the brain uptake pat-
tern was markedly different from that of the passively
diffusing compounds. The brain uptake increased more
than linearly (Fig. 3). Differences in the concentration-
dependent brain uptake profile of the vertebrate Pgp and
the non-Pgp substrates were further investigated by
studying the uptake of the test compounds at 3 and
10 lmol/L exposure concentrations, with and without
co-exposure to a Pgp transporter inhibitor. Since CsA
has poor solubility it is not useful in the locust ex vivo
model where an inhibitor concentration of 25 lmol/L is
used. Instead we used verapamil, a well-studied Pgp
inhibitor, which is used routinely in in vitro models. In
Figure 4 it is seen that Cbz and atenolol uptake were
unaffected by co-exposure to verapamil while verapamil
significantly increased the brain concentration of quini-
dine and loperamide. These observations strongly suggest
that the locust ex vivo model exposed to the vertebrate
Pgp transporter inhibitor verapamil can be used to dis-
criminate between passively diffusing test compounds
and Pgp transporter substrates.
Investigation of energy-dependent efflux
Since Pgp-mediated transport is strictly ATP- and tem-
perature-dependent it should be possible to differentiate a
passively diffusing compound such as Cbz from an
actively effluxed Pgp substrate such as quinidine by com-
paring the locust brain uptake at different temperatures.
Table 1. Drug elimination constants in locust calculated from
C = Coe
kt.
Elimination (h1) SD
Atenolol 1.46 0.14
Propranolol 0.981 0.10
Loperamide 1.15 0.09
Quinidine 0.702 0.14
Administration by injection of 20 lL of 20 lmol/kg dose. From each
animal, 10 lL samples were collected at 0.08, 0.25, 0.75, 2, and 6 h
after administration (n = 6).
1P < 0.0001 atenolol versus propranolol.
2P < 0.0001 loperamide versus quinidine.
Figure 2. Effect of Pgp on locust brain drug distribution in vivo.
Brain:hemolymph ratios of loperamide and rhodamine 123 following
injection of the compounds into the hemolymph with ( ) or without
(■) co-administered Cyclosporine A. Data presented as mean  SD,
n = 6 samples.(*P < 0.05, ***P < 0.001).
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Accordingly, it was found that the passive diffusion of
Cbz into the ex vivo locust brain was markedly increased
when the exposure temperature was raised from 2°C to
30°C (Fig. 5). A corresponding increase in quinidine
uptake was not seen indicating a compensatory and
temperature-dependent increase in Pgp efflux transport
efficiency. This notion was confirmed when the Pgp
transporter was inhibited by verapamil. Here the Pgp sub-
strate quinidine showed temperature-dependent brain
permeation similar to that for the passively diffusing
compound Cbz. These observations strongly indicate that
the difference in brain uptake between Pgp and non-Pgp
substrates in the locust model depends on an active
energy- requiring efflux mechanism similar to vertebrate
Pgp efflux.
Identification of locust Pgp-like protein-
encoding transcripts
Investigation of the sequence similarity between Sg, Dm,
and human Pgp was made by a tblastn search in the Sg
transcriptome data. This search revealed three transcript
Figure 3. Locust brain drug uptake, concentration-dependence. Ex vivo brain uptake of atenolol, carbamezepine, quinidine, and loperamide
following exposure at a concentration of 3, 10, 30, and 100 lmol/L for 5 min. Data presented as mean  SD, n = 3 samples in each group.
(A)
(B)
Figure 4. Effect of Pgp on drug concentration in locust brain. Ex vivo
brain concentration of atenolol, carbamezepine, loperamide, and
quinidine after 5 min exposure at concentrations of 3 lmol/L (Fig. 3A)
and 10 lmol/L (Fig. 3B) with and without verapamil (30 lmol/L). Data
presented as mean  SD, n = 3 samples in each group. (*P < 0.05,
****P < 0.0001).
Figure 5. Effect of temperature on drug concentration in locust
brain. Brain concentration of carbamazepine, quinidine, and
quinidine + verapamil (30 lmol/L) after ex vivo exposure at a
concentration of 3 lmol/L and at the temperatures 30°C or 2°C for
5 min. Data presented as mean  SD, n = 3 samples in each group.
(*P < 0.05, **P < 0.01, ***P < 0.001).
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sequences showing an e-value of 0.0 for both the human
Pgp and the Dm Mdr65 queries (Fig. 6). The fact that
these transcripts indeed encode Pgp/Mdr65 orthologs
was confirmed by the reciprocal blastx search in the
NCBI nr protein database. One of the transcripts
appeared to be represented in the database only as a
partial sequence, since it does not contain the complete
open reading frame. The protein sequences correspond-
ing to the three transcripts were termed Sg-Mdr1, Sg-
Mdr2, and Sg-Mdr3, and they show, respectively, 24.5%
(partial sequence), 36.2%, and 37.2% sequence identity
with the human Pgp, and 22.6% (partial sequence),
32.2%, and 33.1% identity with the Dm Mdr65. The
human Pgp and Dm Mdr65 display 41.4% sequence
identity. Like the human Pgp and the Dm Mdr65, the
Sg-Mdr2 and Sg-Mdr3 sequences contain two conserved
ABC transporter transmembrane domains (http://pfam.
sanger.ac.uk/: pfam00664), as well as two conserved ABC
domains (NCBI Conserved Domains database: cd03249).
The partial Sg-Mdr1 sequence displays one of each
domain, corresponding to the first one present in each
of the other sequences.
Localization of insect brain cells
Histological sections through the brain of both the desert
locust (S. gregaria) (Fig. 1B) and the migratory locust
(Locusta migratoria) (Fig. 7B) showed the typical localiza-
tion of glial and neuronal cell bodies to the peripheral
cortex while the central region of the brain contains neu-
ropil and tracts (Fig. 1B). In some areas of L. migratoria
brain we found only a single layer of cell bodies (Fig. 7B).
The glial cells of this layer are characterized by elongated
nuclei.
Discussion
Compared to the in vivo mouse Pgp KO model the
majority of the developed in vitro screening models do
not reach sufficient accuracy in differentiating Pgp from
non-Pgp substrates (Mahar Doan et al. 2002; Feng et al.
2008; Liu et al. 2008). Recently, zebrafish and insects have
attracted attention for their utility in studies of the verte-
brate BBB (Xie et al. 2010; Geldenhuys et al. 2012) and
insects have been shown to be suitable models for verte-
brate BBB permeability prediction in early drug discovery
(Nielsen et al. 2011; Andersson et al. 2013). These models
make use of the evolutionarily conserved essential mecha-
nisms important in CNS protection, which operate in
mammals and nonvertebrate organisms (Bundgaard and
Abbott 2008; DeSalvo et al. 2011). Despite marked differ-
ences in brain structure between insects and vertebrates
there are many common features at the cellular level of
their brain barriers. In both insects and vertebrates there
is one specific cell layer making up the barrier function.
We have adopted the terminology from earlier studies in
the locust that identified glial cells with elongated nuclei
(Fig. 7B) as constituting the perineurium and function as
the brain barrier (Gocht et al. 2009). Recently the under-
standing of the anatomy of the insect brain barrier has
expanded considerably from studies in Drosophila
(DeSalvo et al. 2011). These studies demonstrate the pres-
ence of two subtypes of surface glia at the Drosophila
brain barrier, the perineurial and the subperineurial glia,
which both appear to form complete layers of ensheath-
ing glial cells that surround the brain. The flattened stel-
late morphology of the perineurial glia may be a reason
for not observing the presence of this glial layer in the
locust light microscopic sections and therefore it may be
suggested that the labeling of the surface perineurial glia
in this study (Fig. 7) corresponds to the subperineurial
glia sheath in Drosophila (DeSalvo et al. 2011). This is the
principal cell layer of the brain chemical protection, and
the laterally localized junctional barriers to paracellular
diffusion are made up of nearly identical and homologous
proteins in vertebrates and insects (Fig. 7) (Wu and Beitel
2004; Danemann and Barres 2005; Banerjee and Bhat
2006; Stork et al. 2008).
Demonstration of homologies and functional parallels
between insect and vertebrate Pgp efflux transporters has
been shown where the Dm Mdr65 transporter was charac-
terized by exhibiting 42% sequence identity to the mam-
malian ABC transporter MDR1/Pgp, being localized at
the periphery of the glia:hemolymph barrier and showing
Pgp efflux properties in Mdr65-transfected human
embryonic kidney (HEK) cells (Mayer et al. 2009). These
observations strongly indicate the homologies between the
insect and mammalian ABC efflux transporters based on
studies on the fly. The transcriptome data presented here
also indicate the homologies between insects (locusts) and
mammals including human.
In this study it was shown that in vivo inhibition of
the Pgp transporter in the locust by CsA resulted in a sig-
nificantly increased brain uptake of both Rho123 and
loperamide, two well-known Pgp substrates. These data
strongly suggest that the locusts have transporter proteins
present in the brain barrier and that these efflux proteins
can be inhibited by CsA as shown in the Dm model
(Mayer et al. 2009). Importantly, locust transcriptome
data show a high degree of identity of the Sg-Mdr1-3 pro-
tein sequences to the human Pgp sequence and conserved
domains indicating that these locust proteins are true Pgp
orthologs, which may correspond to the brain transporter
proteins inhibited by CsA. In addition to the Pgp trans-
porter homologies, the locust has the advantage of being
a large insect with a large-sized brain.
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Screening of potential vertebrate Pgp transporter sub-
strates can be done successfully in transgenic and WT
mice in vivo but these models do not show sufficient cost
efficiency to be used as screening models. Therefore,
sophisticated mammalian in vitro co-culture models have
been developed demonstrating functional expression of
Pgp (Gaillard et al. 2000). However, even these models
are unable to replicate all the physiological functions of a
dynamic brain barrier (Abbott et al. 2010; DeSalvo et al.
2011) and they suffer from complex culture technology
(Mensch et al. 2009). As shown in this study the locust in
vivo model has all the endogenous brain barrier features
and exhibits a relevant structure and function of its brain
barrier. However, this study also shows that intrahem-
olymphic injected test compounds are subject to a rapid
and differential elimination from the hemolymph. Thus,
the brain exposure of the compound is affected by drug-
related elimination over time requiring complex AUC
(area under curve) calculations in order to estimate the
brain-to-plasma ratio. Since the aim with the current
model development was to establish a cost efficient
model, which could be used in drug discovery, we
focused on an ex vivo approach. In this model, the whole
brain is dissected out and exposed at a constant tempera-
ture and substrate concentration. In contrast to both ver-
tebrate and the locust in vivo models the locust ex vivo
(A)
(C)
(B)
(D)
Figure 7. Comparison of the mammalian and locust brain barrier. (A) Cross section through a mammalian brain capillary showing a vascular
endothelial cell with tight junction, the site of the blood-brain barrier. Underlying the endothelium is a basal lamina, which is surrounded by the
endfeet of the astrocytic glial cells. (B) Bisbezimid-stained histological section through the tritocerebral part of a locust (Locusta migratoria) brain
showing the elongated nuclei of perineurial glial cells and nuclei of peripheral cortex glial cells and nerve cell bodies. Outside the perineurium
brain barrier is a neural lamella, stained with fluorescent polystyrene 100 nm nanoparticles (red). (C) Schematic drawing of the mammalian blood-
brain barrier components. To reach its target on a neuronal cell a therapeutic compound in the capillary blood has to cross the endothelial cell
layer, the basal lamina, and the astrocyte layer. (D) In the insect a compound in the hemolymph surrounding the brain has to cross the neural
lamella, the perineurium brain barrier, and in some regions also layers of subperineurium glial cells to reach the brain neurons. Note the marked
difference in number of nucleated cells in the tritocerebral peripheral brain cortex between Locusta migratoria shown here and Schistocerca
gregaria (Fig. 1), used in this study. Therefore, in our proposed model, the locust brain barrier appears to consist of a single layer of elongated
nucleated glial cells.
Figure 6. Comparison of Pgp protein sequence in human, Drosophila, and locust. Multiple sequence alignment of the human Pgp (Hs-mdr1), the
Dm Mdr65 (Dm-mdr65), and the three Sg Pgp/Mdr65 orthologs (Sg-mdr1-3). The protein sequence alignment was performed by Clustal Omega
analysis, available from the European Bioinformatics Institute (Goujon et al. 2010; Sievers et al. 2011). All parameters were set at default values.
The BoxShade algorithm (http://www.ch.embnet.org/software/BOX_form.html) was used for analysis of identical and similar amino acid residues.
Highly conserved residues occurring in at least 60% of the sequences are highlighted in black. Residues similar in chemical nature occurring in at
least 60% of the sequences are highlighted in gray. The consensus line includes the following symbols: “*” representing a particular position at
which an amino acid is conserved in all sequences, “.” representing a position for which at least 60% of the amino acid residues are identical or
similar. (The Sg-mdr1-encoding transcript sequence was only partially retrieved from the available Schistocerca gregaria transcriptome database.)
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model is not affected by a time-dependent decrease in
exposure concentration. By using the whole brain during
the exposure procedure this model represents a significant
step toward a model retaining the relevant in vivo biology
of a dynamic and physiologically functioning brain bar-
rier. In the locust models housed animals of appropriate
ages can be used. This, together with the simplicity by
which the brain is dissected out and incubated makes the
locust ex vivo model easy to handle and it does not
require a complex culture technology typical of recently
developed in vitro models.As expected, the uptake of the
low and high permeability compounds, atenolol and Cbz,
respectively, showed a dose-related linearity in brain
uptake in the ex vivo model. The locust ex vivo model
brain uptake confirmed the difference seen in vertebrate
barrier permeability for the two test compounds, and
confirmed the high dynamic range of the locust model
(ratio of permeabilities for these two compounds is ~64).
By contrast, uptake of the Pgp substrates (loperamide and
quinidine) increased more at higher concentrations, indi-
cating saturation of the Pgp transporter, that is uptake by
diffusion was able to override efflux by the transporter.
Furthermore, the ex vivo model showed that co-treatment
with the vertebrate Pgp transporter inhibitor verapamil
significantly increased the brain uptake of the two Pgp
substrates. The data showed that low permeability com-
pounds such as atenolol can be discriminated from Pgp
substrates such as quinidine by using co-exposure with
verapamil. For model comparison, the quantitative effect
of verapamil is similar to the effect found in a mamma-
lian co-culture model (Culot et al. 2008). These findings
support the evidence that the verapamil-promoted uptake
of the Pgp substrates in the locust is due to the presence
of an efflux transporter that is efficiently inhibited by the
Pgp inhibitor verapamil.The present and recently reported
data (Andersson et al. 2013) show a remarkable similarity
between locust ex vivo and mouse Pgp KO/WT data
(Doran et al. 2005) confirming the accuracy of the locust
model in differentiating Pgp from non-Pgp substrates.
Furthermore, both models showed that CNS (e.g., risperi-
done and citalopram) and non-CNS drugs (e.g., lopera-
mide and quinidine) are affected by Pgp transporter
efflux, confirming that CNS drugs could also be Pgp sub-
strates. In addition to the Pgp efflux transporter, the
breast cancer resistance protein (BCRP or ABCG2) is
localized to the brain of human and mice and found to
be a major efflux transporter at the BBB (Ohtsuki and
Terasaki 2007). In fact, studies on isolated brain capillary
endothelial cells showed that the protein expression of
BCRP was almost two times greater in humans than in
mice while the expression level of Pgp in humans was
about half of that in mice (Uchida et al. 2011). A recent
study of the sequence similarities between the protein
sequence corresponding to the locust Unigene18039
encoded transcript and the human ABCG2 transporter
protein BCRP), showed a 40% identity (Al-qadi, poster
presented at the 16th International Symposium (2013) on
“Signalling in the Blood-Brain Barriers,” Sumeg, Hungary).
The presence of a non-Pgp efflux transporter was also
indicated by the observation of a marked, more than
dose-related, brain uptake of Bupropion, a BRCP trans-
porter substrate, in the locust ex vivo model after
increased exposure concentrations, while the uptake was
unaffected by treatment with the Pgp inhibitor verapamil
(Andersson et al. 2013). These observations may indicate
both the presence and physiological function of a BCRP
transporter homologue in the locust brain barrier. Despite
the common characteristics of locust and mice in
identifying Pgp substrates (Andersson et al. 2013), the
modest sequence identity between the locust and human
Pgp (and likely also BCRP) transporters, indicates poten-
tial species differences in the interaction of specific drugs
with the transporters.The ABC – superfamily efflux trans-
porters play a central role in protecting the brain from
toxic xenobiotics, which also affect the uptake and distri-
bution of drugs to their brain tissue targets. The less well
understood complex network and interactions between
these transporters (Sharom 2008) may warrant the use of
a simplified model indicating whether a test compound is
effluxed by a ATP- binding cassette transporter or not.
Since it is well-known that the Pgp efflux mechanism
in vertebrates is an active process requiring ATP (Li et al.
2010) it was expected that a reduction in the exposure
temperature should reduce both the permeation of pas-
sively diffusing compounds and the efficiency of the efflux
transporters also in the insect model. Indeed, this study
confirmed the utility of a locust ex vivo model where
brain uptake profile at normal and low (energy uncou-
pling) temperature was markedly different for a passively
diffusing compound, Cbz, and a Pgp efflux transported
compound, quinidine. This model may, therefore, play a
role as a first line in the identification of non-specific
efflux transporter substrates of compounds in early drug
discovery.
To obtain an experimental BBB model with no distur-
bance to all the necessary signaling interactions at the
barrier (Danemann and Barres 2005), an optimal model
would be to use an intact brain, exhibiting a natural,
undisturbed, dynamic brain barrier. The locust ex vivo
model fulfills these criteria and showed high reproducibil-
ity, which hence could be useful in compound screening
in the early drug discovery phase. Importantly in this
model there is no choroid plexus or CSF, hence the brain
barrier described is the only layer governing CNS drug
distribution; this simplifies analysis compared to the
mammalian brain. The ex vivo model approach is sup-
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ported by the recently published comprehensive studies
on Dm (Stork et al. 2008; DeSalvo et al. 2011). Despite
the species differences between insects and human, the
model exhibits strong evolutionary conservatism with
respect to the Pgp efflux transporter, making the model a
reliable tool in early drug screening of potential Pgp sub-
strates based on quantitative measurements of brain drug
uptake.
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